-Pembrolizumab (Keytruda) is approved for the treatment of MSI-H or MMR-deficient solid tumors, including gastric cancer, that are unresectable or metastatic and have progressed following prior treatment. Pembrolizumab is an anti-PD-1 antibody that blocks the interaction between PD-1 on T cells and its ligands (PD-L1/PD-L2) on tumor cells, reactivating T cells to attack the tumor. 239 -Trials are evaluating the combination of ICIs with chemotherapy, targeted therapies, and other immunotherapies to enhance antitumor responses in MSI-H gastric cancer. 240, 241 -Research is focused on identifying additional biomarkers that can predict response to immunotherapy in gastric cancer, as well as understanding the mechanisms underlying resistance to ICIs. In sentence co-occurrences: types of therapy and types of cancer